+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liquid Biopsy Market - A Global and Regional Analysis: Focus on Offering, Usage, Workflow, Circulating Biomarker, Sample, Technology, Clinical Application, End User, and Region - Analysis and Forecast, 2022-2032

  • PDF Icon

    Report

  • 263 Pages
  • May 2022
  • Region: Global
  • BIS Research
  • ID: 5157303
10% Free customization

Global Liquid Biopsy Market to Reach $19,066.0 Million by 2032

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

Global Liquid Biopsy Market Industry Overview



The global liquid biopsy market was estimated to be at $2,508.2 million in 2021, which is expected to grow with a CAGR of 19.83% and reach $19,066.0 million by 2032. The growth in the global liquid biopsy market is expected to be driven by increasing adoption of NGS in various research fields, advancement in NGS, and increase in the adoption of personalized medicine.

Market Lifecycle Stage

The global liquid biopsy market is still in the nascent phase. Significant increase in the research and development activities pertaining to next-generation sequencing are underway to develop NGS products and services, which are expected to increase due to the rising number of chronic disease burdens such as cancer. Liquid biopsy is a non-invasive medical procedure which holds the ability to detect the presence of molecular cancer biomarkers in biological fluids. The report includes market estimation for tests/services, instruments, kits and consumables used for liquid biopsies of different oncology and non-oncology disorders. Liquid biopsy has a critical role in the precision medicine approach, as it confirms the safe and effective application of targeted therapeutics. A liquid biopsy helps physicians to analyze tumor-related information through a simple blood test. As researchers are generating data that have the potential to lead to unprecedented biological insight, albeit at the cost of the greater complexity of data analysis. Increasing investments in R&D of liquid biopsy products and services and various research fundings is one of the major opportunities in the global liquid biopsy market.

Impact

  • Rising global prevalence of cancers and the growing need for early detection coupled with efficient treatment monitoring and recurrence detection is anticipated to support the growth of the global liquid biopsy market during the forecast period 2022-2032.
  • The market is expected to grow at a significant growth rate due to opportunities such as the introduction of informatics and technological innovations for a large customer base and increasing adoption of cancer and other disease testing services.

Impact of COVID-19

The current global liquid biopsy market comprises various indications such as lung cancer, breast cancer, prostate cancer, and many others. It has been noticed that there has been a reduction in the capacity or shutdowns of laboratories and other research institutions, which have led to reduced usage of various products and services related to research.

The government imposed various restrictions during COVID-19, such as travel bans, quarantines, curfews, business shutdowns, and closures. This led to an increased cost of the COVID-19-related services. There have been many issues during the COVID-19 pandemic, such as operational failures, shipping issues, inaccurate demand forecasts, and other production issues.

Furthermore, the health and the safety of employees were impacted as COVID-19 reduced the efficacy of employees' work potential. However, the market related to COVID-19 grew during the pandemic as customers were in need of testing services. Overall, the impact of COVID-19 on the market size has been low-moderate. Some market players have reported a slight decline in sales. However, financials are already on their way to recovery. The decline in revenues was mostly a result of the initial phases of the COVID-19 pandemic, which comprised complete lockdowns across countries and major cities, thus interrupting the supply chain. The timeline of impact spanned the end of the first quarter and the second quarter of 2020 for most key markets across the globe. However, the pandemic has played a key role in enhancing the growth prospects of liquid biopsy and is expected to indirectly aid in improving the market growth outlook.

Market Segmentation

by Offering (Testing Service, Kits, Platform, Other Consumables)

The testing service segment accounted for the largest value, holding $1,169.2 million of the market in 2021. This trend is expected to increase during the forecast period, 2022-2032. As a result of growing awareness among the general population, coupled with the increasing prevalence of cancers and other non-oncology indications, there are tremendous growth opportunities in this segment.

by Technology (NGS, PCR, Other Technologies, Emerging Technologies)

The largest share can be attributed to the fact that most of the liquid biopsy services and associated kits in the market are based on NGS. It is anticipated that the NGS segment will grow significantly during the forecast period, 2022-2032.

by Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis and Management)

Among all four segments of workflow, the library preparation segment accounted for the largest share, holding 41.18% of the market in 2021. This trend is expected to decline slightly, owing to the entry of novel sequencing platforms in the market during the forecast period (2022-2032). The existing dominance of this segment is primarily attributed to several library preparation kits that are being offered by liquid biopsy key players in the market.

by Circulating Biomarkers (Circulating Tumor Cells (CTCs), Cell-Free DNA (cfDNA), Circulating Cell-Free RNAs, Exosomes and Extracellular Vesicles and Others, Other Circulating Biomarkers)

The cell-free DNA segment accounted for the largest share, holding 56.95% of the market in 2021. This existing dominance of cell-free DNA is expected to decline during the forecast period 2022- 2032, with the segment holding an estimate of 56.10% share in 2032 . As a result of growth in clinical applications, the overall biomarker segment is expected to exhibit tremendous growth through the forecast period.

by Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other Types of Cancer, Non-Oncology Disorder)

The lung cancer segment accounted for the largest share, holding 28.47% of the market in 2021. The existing dominance of this segment is mainly attributed to several higher prevalence of lung cancer coupled with the existing availability of multiple LDT and few approved liquid biopsies in the market.

by Clinical Application (Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, Diagnosis and Screening)

The treatment monitoring segment accounted for the largest share, holding 46.50% of the market in 2021. The existing dominance of this segment is mainly attributed to the availability of multiple treatments monitoring liquid biopsies that are currently offered by key players for different cancer.

by Usage (Clinical, Research)

The research segment accounted for the largest share of 65.43% of the market in 2021. The share is expected to decline slightly during the forecast period, 2022-2032. The dominance of the provider segment is attributed to the existing availability of multiple research kits and assay of the key players in the liquid biopsy market.

by End User (Academic and Research Institutions, Clinical Laboratories, Pharmaceutical and Biotechnology Companies, Other End Users)

The academic and research institutions segment dominates the global liquid biopsy market. Academic and research institutions are among the primary end users of liquid biopsy. Research organizations constitute integral facilities for companies as well as independent academic research facilities.

by Sample (Blood, Urine, Saliva, Others)

The blood segment accounted for the largest share, holding 89.90% of the market in 2021. This trend is expected to decline slightly during the forecast period, 2022-2032, with the segment estimated to hold an 89.45% share in 2032. It is expected that other sample type-based liquid biopsy will enter the market during the forecast period, and due to this, a very slight decline in the blood-based liquid biopsy segment is expected.

by Region

  • North America - U.S. and Canada
  • Latin America and Middle East - Brazil, Mexico, Saudi Arabia, and Rest-of-Latin America and Middle East
  • Europe - U.K., Germany, Italy, Spain, France, and Rest-of-Europe
  • Asia-Pacific - Japan, China, South Korea, Singapore, Australia, India, and Rest-of-Asia-Pacific
  • Rest-of-the-World

The North America region is expected to dominate the global liquid biopsy market during the forecast period 2022-2032. North America has a high adoption rate of liquid biopsy. Backed by several healthcare companies working in the marketplace, the U.S. has the highest implementation of PCR, NGS, and other technologies.

Recent Developments in the Global Liquid Biopsy Market

  • Product Launch in 2020: Sysmex Corporation launched liquid biopsy RUO kits in EMEA region. The kits name is Plasma-SeqSensei, and it is used for non-small cell lung cancer (NSCLC), melanoma, and thyroid cancer.
  • Partnership: In 2021, Illumina, Inc. collaborated with Bristol Myers Squibb to innovate and enhance companion diagnostics for therapy selection to further precision oncology. TSO 500 ctDNA is one of the first liquid biopsy assays to enable comprehensive genomic profiling for therapy selection.
  • Collaboration: In 2021, QIAGEN collaborated with Sysmex Corporation for the development and commercialization of cancer companion diagnostics using NGS and Plasma-Safe-SeqS technology.

Demand - Drivers and Limitations

Following are the demand drivers for the liquid biopsy market:

  • Rising Cancer Prevalence
  • Increasing Adoption of Inorganic Growth Strategies in the Market
  • Increase in Research Funding from National Cancer Institute

The market is expected to face some limitations too due to the following challenges:

  • Uncertain Reimbursement and Regulatory Policies
  • Expected Implementation of Patient Protection and Affordable Care Act in the U.S

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Product launches and upgrades in the liquid biopsy industry are aimed at advancing the overall technologies in the market to ensure efficient detection of various applications such as treatment monitoring and treatment selection. Several companies, including Illumina, Inc. and NeoGenomics Laboratories, were involved in product innovations.

Competitive Strategy: Enterprises led by the market juggernauts frequently update their product portfolios with innovative and application-specific products to sustain current market competition. Moreover, a detailed competitive benchmarking of the players operating in the global liquid biopsy market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

The top segment players include liquid biopsy manufacturers and service providers that capture around 95% of the presence in the market.

Some of the prominent names established in this market are:

  • Abcodia Ltd.
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • Dxcover Limited
  • Elypta
  • Epic Sciences
  • F. Hoffmann-La Roche Ltd
  • Guardant Health
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • LungLife AI, Inc.
  • Micronoma
  • Natera, Inc.
  • Neogenomics Laboratories
  • PerkinElmer Inc.
  • QIAGEN
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

Table of Contents

1 Market
1.1 Product Definition
1.2 Inclusion and Exclusion

2 Market Scope
2.1 Key Questions Answered in the Report

3 Research Methodology
3.1 Data Sources
3.1.1 Primary Data Source
3.1.2 Secondary Data Sources
3.2 Market Estimation Model
3.3 Criteria for Company Profiling

4 Market Overview
4.1 Addressable Market Size and Growth Potential
4.2 COVID-19 Impact on Global Liquid Biopsy Market
4.2.1 Impact on Market Size

5 Industry Insights
5.1 Recently Launched Product/Services
5.1.1 Recently Launched Product/Services by Major Players
5.2 Regulatory Framework
5.2.1 Regulatory Framework in the U.S
5.2.1.1 Guidelines Recommendation
5.2.2 Regulatory Framework in the European Union (EU)
5.2.3 Regulation in Other Countries
5.3 Reimbursement Scenario
5.4 Financing Scenario
5.4.1 Key Players Patent Portfolio
5.4.2 Key Players Stratification As per Raised Financing Value
5.4.3 Key Players Financing Analysis (by Company)
5.4.4 Financing Analysis, $Million, FY2019-FY2022
5.5 Supply Chain Analysis
5.6 Product Mapping Analysis
5.6.1 By Technology
5.6.2 By Sample Type
5.6.3 By Circulating Biomarker
5.6.4 By Application
5.7 Global Liquid Biopsy Market: Stakeholder Analysis (N=30)
5.7.1 Physicians’ Perception
5.7.1.1 Technology Used for Liquid Biopsy
5.7.1.2 Factors Increasing the Adoption of NGS Based Liquid Biopsy
5.7.1.3 Treatment Guidelines for Different Types of Cancer
5.7.1.4 Challenges for Liquid Biopsy
5.7.2 Payer’s Perception
5.7.2.1 Average Cost by Technology (N=30)
5.7.2.2 Cost Difference across End Users
5.7.2.3 Key Factors for Determining Reimbursement Possibility
5.7.3 Investors’ Perception
5.8 Liquid Biopsy Government Initiatives

6 Market Dynamics
6.1 Market Drivers
6.1.1 Rising Cancer Prevalence
6.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market
6.1.3 Increased Research Funding from National Cancer Institute
6.2 Market Challenges
6.2.1 Uncertain Reimbursement and Regulatory Policies
6.2.2 Expected Implementation of Patient Protection and Affordable Care Act in the U.S
6.3 Market Opportunities
6.3.1 Potential Cost Savings
6.3.2 Existing Applicability in Non-Availability of Tissue Sections for Conventional Biopsy Approaches

7 Competitive Insights
7.1 Corporate Strategies
7.1.1 Synergistic Activities
7.1.2 Acquisitions
7.1.3 Funding and Business Expansion Activities
7.2 Business Strategies
7.2.1 Service/Product Launches
7.3 Market Share Analysis (by Manufacturers)
7.4 Market Share Analysis (by Service Providers)

8 Global Liquid Biopsy Market, by Offering, $Million, 2021-2032
8.1 Overview
8.2 Testing Service
8.3 Kits
8.4 Platform
8.5 Other Consumables

9 Global Liquid Biopsy Market, by Technology, $Million, 2021-2032
9.1 Overview
9.2 Next-Generation Sequencing
9.3 Polymerase Chain Reaction
9.3.1 Digital PCR
9.3.2 Multiplex PCR
9.3.3 Real-Time PCR
9.3.4 Others
9.4 Other Technologies
9.5 Emerging Technologies

10 Global Liquid Biopsy Market, by Workflow, $Million, 2021-2032
10.1 Overview
10.2 Sample Preparation
10.3 Library Preparation
10.4 Sequencing
10.5 Data Analysis and Management

11 Global Liquid Biopsy Market, by Usage, $Million, 2021-2032
11.1 Overview
11.2 Clinical
11.3 Research

12 Global Liquid Biopsy Market, by Sample, $Million, 2021-2032
12.1 Overview
12.2 Blood
12.3 Urine
12.4 Saliva
12.5 Others

13 Global Liquid Biopsy Market, by Circulating Biomarker, $Million, 2021-2032
13.1 Overview
13.2 Circulating Tumor Cells (CTCs)
13.3 Cell-Free DNA (cfDNA)
13.4 Circulating Cell-Free RNAs
13.5 Exosomes and Extracellular Vesicles and Others
13.6 Other Circulating Biomarkers

14 Global Liquid Biopsy Market, by Indication, $Million, 2021-2032
14.1 Overview
14.2 Breast Cancer
14.3 Prostate Cancer
14.4 Lung Cancer
14.5 Colorectal Cancer
14.6 Melanoma
14.7 Other Types of Cancer
14.8 Non-Oncology Disorder

15 Global Liquid Biopsy Market, by Clinical Application, $Million, 2021-2032
15.1 Overview
15.2 Treatment Monitoring
15.3 Prognosis and Recurrence Monitoring
15.4 Treatment Selection
15.5 Diagnosis and Screening

16 Global Liquid Biopsy Market, by End User, $Million, 2021-2032
16.1 Overview
16.1.1 Academic and Research Institutions
16.1.2 Clinical Laboratories
16.1.3 Pharmaceutical and Biotechnology Companies
16.1.4 Other End Users

17 Region
17.1 Overview
17.2 North America
17.2.1 U.S.
17.2.2 Canada
17.3 Europe
17.3.1 Germany
17.3.2 France
17.3.3 U.K.
17.3.4 Italy
17.3.5 Spain
17.3.6 Rest-of-Europe
17.4 Asia-Pacific
17.4.1 China
17.4.2 Japan
17.4.3 India
17.4.4 Australia
17.4.5 South Korea
17.4.6 Singapore
17.4.7 Rest-of-Asia-Pacific
17.5 Latin America and Middle East
17.5.1 Brazil
17.5.2 Mexico
17.5.3 Saudi Arabia
17.5.4 Rest-of-Latin America and Middle East
17.6 Rest-of-the-World

18 Market - Competitive Benchmarking & Company Profiles
18.1 Overview
18.2 Abcodia Ltd.
18.2.1 Company Overview
18.2.2 Role of Abcodia Ltd. in the Liquid Biopsy Market
18.2.3 Key Customers of the Company
18.2.4 Key Competitors of the Company
18.2.5 Corporate Strategies
18.2.6 Analyst Perspective
18.3 Bio-Rad Laboratories, Inc.
18.3.1 Company Overview
18.3.2 Role of Bio-Rad Laboratories, Inc. in the Global Liquid Biopsy Market
18.3.3 Key Competitors of the Company
18.3.4 Key Customers of the Company
18.3.5 Corporate Strategies
18.3.6 Financials
18.3.7 Key Insights about the Financial Health of the Company
18.3.8 Analyst’s Perspective
18.4 Biocept, Inc.
18.4.1 Company Overview
18.4.2 Role of Biocept, Inc. in the Global Liquid Biopsy Market
18.4.3 Key Customers of the Company
18.4.4 Key Competitors of the Company
18.4.5 Corporate Strategies
18.4.6 Business Strategies
18.4.7 Financials
18.4.8 Key Insights about the Financial Health of the Company
18.4.9 Analyst’s Perspective
18.5 Dxcover Limited
18.5.1 Company Overview
18.5.2 Role of Dxcover Limited in the Global Liquid Biopsy Market
18.5.3 Key Customers of the Company
18.5.4 Key Competitors of the Company
18.5.5 Dxcover Platform Workflow
18.5.6 Collaboration and Partnership of Dxcover Limited
18.5.7 Corporate Strategies
18.5.8 Analyst Perspective
18.6 Elypta
18.6.1 Company Overview
18.6.2 Role of Elypta Limited in the Global Liquid Biopsy Market
18.6.3 Key Customers of the Company
18.6.4 Key Competitors of the Company
18.6.5 Corporate Strategies
18.6.6 Analyst’s Perspective
18.7 Epic Sciences
18.7.1 Company Overview
18.7.2 Role of Epic Sciences in the Global Liquid Biopsy Market
18.7.3 Key Customers of the Company
18.7.4 Key Competitors of the Company
18.7.5 Corporate Strategies
18.7.6 Analyst’s Perspective
18.8 F. Hoffmann-La Roche Ltd
18.8.1 Company Overview
18.8.2 Role of F. Hoffmann-La Roche Ltd in the Global Liquid Biopsy Market
18.8.3 Key Competitors of the Company
18.8.4 Key Customers of the Company
18.8.5 Business Strategies
18.8.6 Financials
18.8.7 Key Insights about the Financial Health of the Company
18.8.8 Analyst’s Perspective
18.9 Guardant Health
18.9.1 Company Overview
18.9.2 Role of Guardant Health in the Global Liquid Biopsy Market
18.9.3 Key Customers of the Company
18.9.4 Key Competitors of the Company
18.9.5 Business Strategies
18.9.6 Financials
18.9.7 Key Insights about the Financial Health of the Company
18.9.8 Analyst’s Perspective
18.1 Illumina, Inc.
18.10.1 Company Overview
18.10.2 Role of Illumina, Inc. in the Global Liquid Biopsy Market
18.10.3 Key Competitors of the Company
18.10.4 Key Customers of the Company
18.10.5 Corporate Strategies
18.10.6 Financials
18.10.7 Key Insights about the Financial Health of the Company
18.10.8 Analyst’s Perspective
18.11 Laboratory Corporation of America Holdings
18.11.1 Company Overview
18.11.2 Role of Laboratory Corporation of America Holdings in the Global Liquid Biopsy Market
18.11.3 Key Customers of the Company
18.11.4 Key Competitors of the Company
18.11.5 Corporate Strategies
18.11.6 Financials
18.11.7 Analyst’s Perspective
18.12 LungLife AI, Inc.
18.12.1 Company Overview
18.12.2 Role of LungLife AI, Inc. in the Global Liquid Biopsy Market
18.12.3 Key Customers of the Company
18.12.4 Key Competitors of the Company
18.12.5 Corporate Strategies
18.12.6 Analyst’s Perspective
18.13 Micronoma
18.13.1 Company Overview
18.13.2 Role of Micronoma in the Global Liquid Biopsy Market
18.13.3 Key Competitors of the Company
18.13.4 Micronoma: Oncobiota Platform Design Overview
18.13.5 Research Partners of Micronoma
18.13.6 Investors of Micronoma
18.13.7 Corporate Strategies
18.13.8 Analyst Perspectives
18.14 Natera, Inc.
18.14.1 Company Overview
18.14.2 Role of Natera, Inc. Limited in the Global Liquid Biopsy Market
18.14.3 Key Customers of the Company
18.14.4 Key Competitors of the Company
18.14.5 Corporate Strategies
18.14.6 Financials
18.14.7 Key Insights about the Financial Health of the Company
18.14.8 Analyst’s Perspective
18.15 Neogenomics Laboratories
18.15.1 Company Overview
18.15.2 Role of Neogenomics Laboratories in the Global Liquid Biopsy Market
18.15.3 Key Competitors of the Company
18.15.4 Key Customers of the Company
18.15.5 Corporate Strategies
18.15.6 Financials
18.15.7 Key Insights about the Financial Health of the Company
18.15.8 Analyst’s Perspective
18.16 PerkinElmer Inc.
18.16.1 Company Overview
18.16.2 Role of PerkinElmer Inc. in the Global Liquid Biopsy Market
18.16.3 Key Competitors of the Company
18.16.4 Key Customers of the Company
18.16.5 Corporate Strategies
18.16.6 Financials
18.16.7 Key Insights about the Financial Health of the Company
18.16.8 Analyst’s Perspective
18.17 QIAGEN
18.17.1 Company Overview
18.17.2 Role of QIAGEN in the Global Liquid Biopsy Market
18.17.3 Key Competitors of the Company
18.17.4 Key Customers of the Company
18.17.5 Corporate Strategies
18.17.6 Business Strategies
18.17.7 Financials
18.17.8 Key Insights about the Financial Health of the Company
18.17.9 Analyst’s Perspective
18.18 Sysmex Corporation
18.18.1 Company Overview
18.18.2 Role of Sysmex Corporation in the Global Liquid Biopsy Testing Market
18.18.3 Key Competitors of the Company
18.18.4 Key Customers of the Company
18.18.5 Corporate Strategies
18.18.6 Business Strategies
18.18.7 Financials
18.18.8 Key Insights about the Financial Health of the Company
18.18.9 Analyst’s Perspective
18.19 Thermo Fisher Scientific Inc.
18.19.1 Company Overview
18.19.2 Role of Thermo Fisher Scientific Inc. in the Global Liquid Biopsy Market
18.19.3 Key Competitors of the Company
18.19.4 Key Customers of the Company
18.19.5 Corporate Strategies
18.19.6 Financials
18.19.7 Key Insights about the Financial Health of the Company
18.19.8 Analyst’s Perspective

List of Figures
Figure 1: Type of Cancer Diagnostics
Figure 2: Global Liquid Biopsy Market Dynamics
Figure 3: Global Liquid Biopsy Market (by Technology), $Million, 2021 and 2032
Figure 4: Global Liquid Biopsy Market (by Workflow), $Million, 2021 and 2032
Figure 5: Global Liquid Biopsy Market (by Usage), $Million, 2021 and 2032
Figure 6: Global Liquid Biopsy Market (by Sample), $Million, 2021 and 2032
Figure 7: Global Liquid Biopsy Market (by Circulating Biomarker), $Million, 2021 and 2032
Figure 8: Global Liquid Biopsy Market (by Offering), $Million, 2021 and 2032
Figure 9: Global Liquid Biopsy Market (by Indication), $Million, 2021 and 2032
Figure 10: Global Liquid Biopsy Market (by Clinical Application), $Million, 2021 and 2032
Figure 11: Global Liquid Biopsy Market (by End User), $Million, 2021 and 2032
Figure 12: Global Liquid Biopsy Market (by Region), $Million, 2021
Figure 13: Global Liquid Biopsy Market Segmentation
Figure 14: Global Liquid Biopsy Market Research Methodology
Figure 15: Primary Research Methodology
Figure 16: Bottom-Up Approach (Segment-Wise Analysis)
Figure 17: Top-Down Approach (Segment-Wise Analysis)
Figure 18: Global Liquid Biopsy Market, $Million, 2021-2032
Figure 19: Global Liquid Biopsy Market, $Million, 2021-2032
Figure 20: Pre-COVID-19 and Post-COVID-19 Scenario of Global Liquid Biopsy Market, $Million, 2020-2026
Figure 21: Impact of COVID-19 on Liquid Biopsy Market
Figure 22: Financing Analysis (by Company), $Million, FY2019-FY2022
Figure 23: Liquid Biopsy Supply Chain Analysis
Figure 24: Global Liquid Biopsy Market Dynamics
Figure 25: Number of New Cases of Cancer, 2020
Figure 26: Share of Different Cancer Patients
Figure 27: Synergistic Activities, 2020-2021
Figure 28: Research Funding for Different Cancer Types, 2020
Figure 29: Year-on-Year Fiscal Budget of NCI, $Million, 2015-2020
Figure 30: Share of Key Developments and Strategies, January 2019-May 2022
Figure 31: Synergistic Activities Share (by Company), January 2019-May 2022
Figure 32: Acquisitions Share (by Company), January 2019-May 2022
Figure 33: Funding and Business Expansion Activities (by Company), January 2019-May 2022
Figure 34: Service/Product Launches (by Company), January 2019-May 2022
Figure 35: Global Liquid Biopsy Market Share Analysis (by Product Manufacturers), 2020 and 2021
Figure 36: Global Liquid Biopsy Market Share Analysis (Service Providers), 2020 and 2021
Figure 37: Global Liquid Biopsy Market (by Offering)
Figure 38: Share of Global Liquid Biopsy Market (by Offering), $Million, 2021 and 2032
Figure 39: Global Liquid Biopsy Market (Testing Service), $Million, 2021-2032
Figure 40: Global Liquid Biopsy Market (Kits), $Million, 2021-2032
Figure 41: Global Liquid Biopsy Market (Platform), $Million, 2021-2032
Figure 42: Global Liquid Biopsy Market (Other Consumables), $Million, 2021-2032
Figure 43: Global Liquid Biopsy Market (by Technology), $Million, 2021 and 2032
Figure 44: Global Liquid Biopsy Market (Next-Generation Sequencing), $Million, 2021-2032
Figure 45: Global Liquid Biopsy Market (Polymerase Chain Reaction), $Million, 2021-2032
Figure 46: Global Liquid Biopsy Market (Digital PCR), $Million, 2021-2032
Figure 47: Global Liquid Biopsy Market (Multiplex PCR), $Million, 2021-2032
Figure 48: Global Liquid Biopsy Market (Real-Time PCR), $Million, 2021-2032
Figure 49: Global Liquid Biopsy Market (Others), $Million, 2021-2032
Figure 50: Global Liquid Biopsy Market (Other Technologies), $Million, 2021-2032
Figure 51: Global Liquid Biopsy Market (by Emerging Technologies), $Million, 2021-2032
Figure 52: Global Liquid Biopsy Market (by Workflow)
Figure 53: Global Liquid Biopsy Market (by Workflow), 2021 vs. 2032
Figure 54: Global Liquid Biopsy Market (Sample Preparation), 2021-2032
Figure 55: Global Liquid Biopsy Market (Library Preparation), 2021-2032
Figure 56: Global Liquid Biopsy Market (Sequencing), 2021-2032
Figure 57: Global Liquid Biopsy Market (Data Analysis and Management), 2021-2032
Figure 58: Global Liquid Biopsy Market (by Usage)
Figure 59: Global Liquid Biopsy Market (by Usage), 2021 vs. 2032
Figure 60: Global Liquid Biopsy Market (Clinical), 2021-2032
Figure 61: Global Liquid Biopsy Market (Research), 2021-2032
Figure 62: Global Liquid Biopsy Market (by Sample)
Figure 63: Global Liquid Biopsy Market (by Sample), 2021 vs. 2032
Figure 64: Global Liquid Biopsy Market (Blood), 2021-2032
Figure 65: Global Liquid Biopsy Market (Urine), 2021-2032
Figure 66: Global Liquid Biopsy Market (Saliva), 2021-2032
Figure 67: Global Liquid Biopsy Market (by Others), 2021-2032
Figure 68: Global Liquid Biopsy Market (by Circulating Biomarker
Figure 69: Global Liquid Biopsy Market (by Circulating Biomarker), 2021 vs. 2032
Figure 70: Global Liquid Biopsy Market (Circulating Tumor Cells), 2021-2032
Figure 71: Global Liquid Biopsy Market (Cell-Free DNA), 2021-2032
Figure 72: Global Liquid Biopsy Market (Circulating Cell-Free RNAs), 2021-2032
Figure 73: Global Liquid Biopsy Market (Exosomes and Extracellular Vesicles), 2021-2032
Figure 74: Global Liquid Biopsy Market (by Other Circulating Biomarkers), 2021-2032
Figure 75: Global Liquid Biopsy Market (by Indication)
Figure 76: Global Liquid Biopsy Market (by Indication), 2021 vs. 2032
Figure 77: Global Liquid Biopsy Market (Breast Cancer), 2021-2032
Figure 78: Global Liquid Biopsy Market (Prostate Cancer), 2021-2032
Figure 79: Global Liquid Biopsy Market (Lung Cancer), 2021-2032
Figure 80: Global Liquid Biopsy Market (Colorectal Cancer), 2021-2032
Figure 81: Global Liquid Biopsy Market (Melanoma), 2021-2032
Figure 82: Global Liquid Biopsy Market (by Other Types of Cancer), 2021-2032
Figure 83: Global Liquid Biopsy Market (Non-Oncology Disorder), 2021-2032
Figure 84: Global Liquid Biopsy Market (by Clinical Application)
Figure 85: Global Liquid Biopsy Market (by Clinical Application), 2021 vs. 2032
Figure 86: Global Liquid Biopsy Market (Treatment Monitoring), 2021-2032
Figure 87: Global Liquid Biopsy Market (Prognosis and Recurrence Monitoring), 2021-2032
Figure 88: Global Liquid Biopsy Market (Treatment Selection), 2021-2032
Figure 89: Global Liquid Biopsy Market (Diagnosis and Screening), 2021-2032
Figure 90: Global Liquid Biopsy Market (by End User), 2021 vs. 2032
Figure 91: Global Liquid Biopsy Market (Academic and Research Institutions), $Million, 2021-2032
Figure 92: Global Liquid Biopsy Market (Clinical Laboratories), $Million, 2021-2032
Figure 93: Global Liquid Biopsy Market (Pharmaceutical and Biotechnology Companies), $Million, 2021-2032
Figure 94: Global Liquid Biopsy Market (Other End Users), $Million, 2021-2032
Figure 95: Global Liquid Biopsy Market (by Region), $Million, 2021-2032
Figure 96: Global Liquid Biopsy Market (by North America), 2021 vs. 2032
Figure 97: North America Liquid Biopsy Market, $Million, 2021-2032
Figure 98: North America Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 99: Market Dynamics of North America Liquid Biopsy Market
Figure 100: U.S. Liquid Biopsy Market, 2021-2032
Figure 101: U.S. Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 102: Canada Liquid Biopsy Market, 2021-2032
Figure 103: Canada Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 104: Global Liquid Biopsy Market (by Europe), 2021 vs. 2032
Figure 105: Europe Liquid Biopsy Market, $Million, 2021-2032
Figure 106: Europe Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 107: Market Dynamics of the Europe Liquid Biopsy Market
Figure 108: Germany Liquid Biopsy Market, 2021-2032
Figure 109: Germany Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 110: France Liquid Biopsy Market, 2021-2032
Figure 111: France Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 112: U.K. Liquid Biopsy Market, 2021-2032
Figure 113: U.K. Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 114: Italy Liquid Biopsy Market, 2021-2032
Figure 115: Italy Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 116: Spain Liquid Biopsy Market, 2021-2032
Figure 117: Spain Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 118: Rest-of-Europe Liquid Biopsy Market, 2021-2032
Figure 119: Rest-of-Europe Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 120: Global Liquid Biopsy Market (by Asia-Pacific), 2021 vs. 2032
Figure 121: Asia-Pacific Liquid Biopsy Market, $Million, 2021-2032
Figure 122: Asia-Pacific Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 123: Market Dynamics of Asia-Pacific Liquid Biopsy Market
Figure 124: China Liquid Biopsy Market, 2021-2032
Figure 125: China Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 126: Japan Liquid Biopsy Market, 2021-2032
Figure 127: Japan Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 128: India Liquid Biopsy Market, 2021-2032
Figure 129: India Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 130: Australia Liquid Biopsy Market, 2021-2032
Figure 131: Australia Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 132: South Korea Liquid Biopsy Market, 2021-2032
Figure 133: South Korea Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 134: Singapore Liquid Biopsy Market, 2021-2032
Figure 135: Singapore Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 136: Rest-of-Asia-Pacific Liquid Biopsy Market, 2021-2032
Figure 137: Rest-of-Asia-Pacific Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 138: Global Liquid Biopsy Market (by Latin America and Middle East), 2021 vs. 2032
Figure 139: Latin America and Middle East Liquid Biopsy Market, $Million, 2021-2032
Figure 140: Latin America and Middle East Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 141: Market Dynamics of Latin America and Middle Eastern Liquid Biopsy Market
Figure 142: Brazil Liquid Biopsy Market, 2021-2032
Figure 143: Brazil Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 144: Mexico Liquid Biopsy Market, 2021-2032
Figure 145: Mexico Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 146: Saudi Arabia Liquid Biopsy Market, 2021-2032
Figure 147: Saudi Arabia Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 148: Rest-of-Latin America and Middle East Liquid Biopsy Market, 2021-2032
Figure 149: Rest-of-Latin America and Middle East Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 150: Rest-of-the-World Liquid Biopsy Market, 2021-2032
Figure 151: Rest-of-the-World Liquid Biopsy Market, Thousand Units, 2021-2032
Figure 152: Total Number of Companies Profiled
Figure 153: Abcodia Ltd.: Product Portfolio
Figure 154: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 155: Bio-Rad Laboratories, Inc.: Overall Financials, 2019-2021
Figure 156: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2019-2021
Figure 157: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2019-2021
Figure 158: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2019-2021
Figure 159: Biocept, Inc.: Portfolio
Figure 160: Biocept, Inc.: Overall Financials, 2019-2021
Figure 161: Biocept, Inc.: R&D Expenditure, 2019-2021
Figure 162: Dxcover Limited: Product Portfolio
Figure 163: Dxcover Limited: Dxcover Platform Workflow
Figure 164: Dxcover Limited: Collaboration and Partnership of Dxcover Limited
Figure 165: Elypta: Product Portfolio
Figure 166: Epic Sciences: Portfolio
Figure 167: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 168: F. Hoffmann-La Roche Ltd: Overall Financials, 2019-2021
Figure 169: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2019-2021
Figure 170: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2019-2021
Figure 171: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2020
Figure 172: Guardant Health: Portfolio
Figure 173: Guardant Health: Overall Financials, 2019-2021
Figure 174: Guardant Health: Sales (by Segment), 2019-2021
Figure 175: Guardant Health: Sales (by Region), 2019-2021
Figure 176: Guardant Health: R&D Expenditure, 2019-2021
Figure 177: Illumina, Inc.: Product Portfolio
Figure 178: Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 179: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 180: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 181: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 182: Laboratory Corporation of America Holdings: Overall Product Portfolio
Figure 183: Laboratory Corporation of America Holdings: Overall Financials, 2019-2021
Figure 184: Laboratory Corporation of America Holdings: Revenue (by Segment), 2019-2021
Figure 185: Laboratory Corporation of America Holdings: Revenue (by Region), 2019-2021
Figure 186: LungLife AI, Inc.: Portfolio
Figure 187: Micronoma: Oncobiota Platform Design Overview
Figure 188: Micronoma: Research Partners of Micronoma
Figure 189: Micronoma: Product Portfolio
Figure 190: Natera, Inc.: Product Portfolio
Figure 191: Natera, Inc.: Overall Financials, 2019-2021
Figure 192: Natera, Inc.: Sales (by Segment), 2019-2021
Figure 193: Natera, Inc.: R&D Expenditure, 2019-2021
Figure 194: Neogenomics Laboratories: Overall Product Portfolio
Figure 195: Neogenomics Laboratories: Overall Financials, 2019-2021
Figure 196: Neogenomics Laboratories: Revenue (by Segment), 2019-2021
Figure 197: Neogenomics Laboratories: R&D Expenditure, 2019-2021
Figure 198: PerkinElmer Inc.: Product Portfolio
Figure 199: PerkinElmer Inc.: Overall Financials, $Million, 2019-2021
Figure 200: PerkinElmer Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 201: PerkinElmer Inc.: Revenue (by Region), $Million, 2019-2021
Figure 202: PerkinElmer Inc.: R&D Expenditure, $Million, 2019-2021
Figure 203: QIAGEN: Overall Product Portfolio
Figure 204: QIAGEN: Overall Financials, 2019-2021
Figure 205: QIAGEN: Revenue (by Segment), 2019-2021
Figure 206: QIAGEN: Revenue (by Region), 2019-2021
Figure 207: QIAGEN: R&D Expenditure, 2019-2021
Figure 208: Sysmex Corporation: Overall Product Portfolio
Figure 209: Sysmex Corporation: Overall Financials, 2018-2020
Figure 210: Sysmex Corporation: Revenue (by Region), 2018-2020
Figure 211: Sysmex Corporation: R&D Expenditure, 2018-2020
Figure 212: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 213: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
Figure 214: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), $Million, 2019-2021
Figure 215: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
Figure 216: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021

List of Tables
Table 1: Most Common Cancers
Table 2: Global Liquid Biopsy Market (by Region), $Million, 2021-2032
Table 3: COVID-19 Impact on Global Liquid Biopsy Market
Table 4: Products and Services Launched by Various Key Players for Liquid Biopsy Research
Table 5: Launched Liquid Biopsy Tests from Major Players
Table 6: Reimbursement Scenario for Key Players' Offerings in the Global Liquid Biopsy Market
Table 7: Global Liquid Biopsy Market: Key Players Patent Portfolio
Table 8: Liquid Biopsy Product Mapping Analysis (by Technology)
Table 9: Liquid Biopsy Product Mapping Analysis (by Sample)
Table 10: Liquid Biopsy Product Mapping Analysis (by Circulating Biomarker)
Table 11: Liquid Biopsy Product Mapping Analysis (by Application)
Table 12: Government Initiatives for Liquid Biopsies
Table 13: Pricing List of Key Players’ Liquid Biopsies
Table 14: List of Companies Providing Testing Services
Table 15: List of Companies Providing Kits
Table 16: List of Companies Providing Platform
Table 17: List of Companies Providing Other Consumables

Samples

Loading
LOADING...

Companies Mentioned

  • Abcodia Ltd.
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • Chronix Biomedical
  • Cynvenio Biosystems, Inc.
  • Epic Sciences, Inc.
  • F. Hoffmann-La Roche AG
  • GUARDANT HEALTH, INC
  • Illumina, Inc.
  • Menarini Silicon Biosystems, Inc.
  • NeoGenomics Laboratories, Inc.
  • Personal Genome Diagnostics, Inc.
  • Qiagen N.V.
  • Resolution Bioscience, Inc.
  • Thermo Fisher Scientific

Table Information